Rapport Therapeutics (RAPP) investor relations material

Leadership and expertise

• Executive team and board have extensive experience in neuroscience, biotech, and pharma, with backgrounds at major companies and successful track records in drug development and commercialization.

Precision neuroscience platform and pipeline

• Focus on small molecule precision medicines for neurological and psychiatric disorders, leveraging differentiated pharmacology for high selectivity and specificity.

• Lead program RAP-219 targets TARPγ8, a receptor associated protein, with robust Phase 2a data in drug-resistant focal onset seizures (FOS) and a Phase 3 program initiated in Q2 2026.

• Pipeline includes programs for primary generalized tonic-clonic seizures (PGTCS), bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.

RAP-219 clinical data and market opportunity

• RAP-219 demonstrated a 71% reduction in long episodes and 78% reduction in clinical seizures in Phase 2a FOS trial, with 24% achieving seizure freedom at 8 weeks.

• Efficacy was consistent across baseline disease severity and sustained over 16 weeks, with a favorable safety profile and 10% discontinuation rate due to adverse events.

• RAP-219 addresses a ~$15B market in FOS, ~$7B in PGTCS, and ~$45B in bipolar mania, with potential to double peak revenue through a long-acting injectable (LAI) formulation.